Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN has a CSO who started his own repurposed drug company!!!

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Jan 13, 2021 11:32pm

136 Views

Post# 32291753

RE:AGN has a CSO who started his own repurposed drug company!!!

Algernon, I am so glad you have finally realized the game. Perhaps go back and read the messages I wrote on the board ( when you blocked me ). I understand you won't apologize but I hope you didn't learn the hard way.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale